Thilo Bayrhoffer

Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation.

Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation.

Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation.

Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation.